First Time Loading...

JW (Cayman) Therapeutics Co Ltd
HKEX:2126

Watchlist Manager
JW (Cayman) Therapeutics Co Ltd Logo
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Watchlist
Price: 1.87 HKD 1.63% Market Closed
Updated: May 9, 2024

Gross Margin
JW (Cayman) Therapeutics Co Ltd

50.7%
Current
29%
Average
62%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
50.7%
=
Gross Profit
88.2m
/
Revenue
173.9m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CN
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
771.2m HKD
51%
US
Abbvie Inc
NYSE:ABBV
283.3B USD
66%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
66%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
107.9B USD
87%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
105.3B USD
86%
AU
CSL Ltd
ASX:CSL
135.1B AUD
52%
US
Gilead Sciences Inc
NASDAQ:GILD
80.9B USD
76%
US
Moderna Inc
NASDAQ:MRNA
46.7B USD
22%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
US
Biogen Inc
NASDAQ:BIIB
32B USD
75%
KR
Celltrion Inc
KRX:068270
40.3T KRW
48%
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Country CN
Market Cap 771.2m HKD
Gross Margin
51%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 283.3B USD
Gross Margin
66%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 164.8B USD
Gross Margin
66%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 107.9B USD
Gross Margin
87%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 105.3B USD
Gross Margin
86%
CSL Ltd
ASX:CSL
Country AU
Market Cap 135.1B AUD
Gross Margin
52%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 80.9B USD
Gross Margin
76%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 46.7B USD
Gross Margin
22%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Gross Margin
75%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 32B USD
Gross Margin
75%
Celltrion Inc
KRX:068270
Country KR
Market Cap 40.3T KRW
Gross Margin
48%

Profitability Report

View the profitability report to see the full profitability analysis for JW (Cayman) Therapeutics Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
50.7%
=
Gross Profit
88.2m
/
Revenue
173.9m
What is the Gross Margin of JW (Cayman) Therapeutics Co Ltd?

Based on JW (Cayman) Therapeutics Co Ltd's most recent financial statements, the company has Gross Margin of 50.7%.

ALPHA SPREAD
Join more than 135,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.